BioSpace News Archive

Tiziana Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS) today announces its intention to apply for admission to listing of its ordinary shares (the “Ordinary Shares”) on the standard listing segment of the Official List of the Financial Conduct Authority (the “Official List”) and admission to trading on the London Stock Exchange plc’s

Civic Health Project, a Silicon Valley based grantmaking organization dedicated to reducing toxic partisanship in the United States, today announced the launch of its Academic Research Council and Advisory Council.

San Diego, Speid & Associates announces that Drug Development Boot Camp® will take place at The Harvard Club, 374 Commonwealth Avenue, Boston, on November 18-19, 2020., and virtually in real time, for those who cannot attend in person.

Sound Pharmaceuticals (SPI) is pleased to announce the filing of an Investigational New Drug Application with the FDA to begin Phase 2 studies to prevent and treat COVID-19

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference on Thursday, August 6, 2

PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively “Noden”) to Stanley Capital (“Stanley Capital”). The total value of the transaction will resul

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report second quarter 2020 financial results on Thursday, August 6, 2020 , before the market opens.

Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate ®

SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce fully human polyclonal antibodies without the need for human donors, today announced that the first participant has been dosed in its Phase 1 clinical trial evaluating SAB-176 for the treatment of seasonal influenza. SAB-176 is a novel anti-influenza human immunoglobulin G (IgG) immunotherapy desig

Today Essity, a leading global hygiene and health company and the maker of TENA incontinence and skin care products announced new findings from a recent consumer survey of incontinence sufferers that uncovered a surprising truth: most women are living with intimate skin irritation, yet are not using the right incontinence products or addressing these issues with their doctor